Markets:

Overview

News

Currencies

International

Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

39.47 +1.36 (+3.57%)

Streaming Delayed Price Updated: 3:39 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zenas BioPharma, Inc. - Common Stock

< Previous 1 2 3 Next >

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

November 11, 2025

From Zenas BioPharma

Via GlobeNewswire

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗

October 28, 2025

Via MarketBeat

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 27, 2025

Via Benzinga

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

October 27, 2025

From Zenas BioPharma

Via GlobeNewswire

Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 ↗

October 16, 2025

Via The Motley Fool

Topics Regulatory Compliance

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug ↗

October 08, 2025

Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 million in private placement.

Via Benzinga

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

October 08, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

September 02, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

August 26, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025

From Zenas BioPharma

Via GlobeNewswire

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 16, 2025

From The Schall Law Firm

Via Business Wire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 16, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 12, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ZBIO DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO

June 10, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm

June 09, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm

June 02, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 02, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 02, 2025

From Pomerantz LLP

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

June 01, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

May 29, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025

From Zenas BioPharma

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

May 28, 2025

From Pomerantz LLP

Via GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

May 26, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.